Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL OPUS III
- Development stage
- Preclinical
- Lead developer
- Biolingus
- Modality
- Peptides
- Administration
- Sublingual
01
Overview
Biolingus is developing **BL OPUS III**, a sublingual formulation of the GLP-1 receptor agonist **exenatide**, for the treatment of type 2 diabetes. Utilizing the proprietary **OPUS (Oral Peptide Utility System)** technology, this formulation aims to provide a non-invasive alternative to traditional injectable GLP-1 therapies. Exenatide works by mimicking the action of the endogenous glucagon-like peptide-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. The sublingual delivery is designed to improve patient compliance and accessibility, particularly in emerging markets where affordability and ease of administration are critical. The drug is currently in the preclinical stage of development.
- Other names
- sublingual exenatideexenatide (sublingual formulation)Biolingus-GLP-1 receptor-peptide (sublingual formulation)
02
Targets
Beyond the preview
Go deeper on BL OPUS III.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL OPUS III.